

Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK T: +44 (0)118 9656 300 F: +44 (0)118 9656 356 info@intersurgical.com www.intersurgical.com

January 2020

To whom it may concern:

The complete range of Intersurgical breathing filters has been validated against the passage of a variety of bacterial and viral species of varying particle sizes.

The Clear-Guard 3 filtration device (code 1544000) has been independently validated against the passage of *Bacillus subtilis* (1.0µm x 0.7µm) and ϕ 174 bacteriophage (0.027µm) to represent the bacterial and viral challenge it may face in the clinical environment. These tests show the filter to be >99.99% efficient against these challenge organisms.

The challenge presented in the viral test protocol (ϕ 174 bacteriophage, 0.027 µm) will be at least as severe as that posed by the Coronavirus (2019-nCov) which originated in Wuhan PRC (0.05 - 0.1µm).

As such, it can be concluded that the 1544 range of products will provide at least the same level of quoted efficiency (>99.99%) as reported in the independent microbiology tests when challenged with Coronavirus. Copies of these test protocols are available upon request.

Ivan Seniut Group Quality and Regulatory Affairs Director Duly authorised for and on behalf of Intersurgical Ltd